# Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19

> **NCT04373707** · PHASE4 · COMPLETED · sponsor: **Central Hospital, Nancy, France** · enrollment: 1000 (actual)

## Conditions studied

- COVID
- Thrombosis
- Pulmonary Embolism
- Deep Vein Thrombosis

## Interventions

- **DRUG:** Enoxaparin
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT04373707
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-13
- **Primary completion:** 2021-04-29
- **Final completion:** 2021-09-14
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2023-08-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04373707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04373707, "Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04373707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*